|Traded as||NASDAQ: ACOR
S&P 600 Component
|Headquarters||Ardsley, New York, United States|
|Ron Cohen (CEO)
Andrew R. Blight
|Revenue||US$292.2 Million (FY 2011)|
|US$35.1 Million (FY 2011)|
|US$30.6 Million (FY 2011)|
|Total assets||US$379.5 Million (FY 2011)|
|Total equity||US$205.2 Million (FY 2011)|
Number of employees
|328 (February, 2012) |
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.
As of December 31, 2013[update], the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.
None of the audio/visual content is hosted on this site. All media is embedded from other sites such as GoogleVideo, Wikipedia, YouTube etc. Therefore, this site has no control over the copyright issues of the streaming media.
All issues concerning copyright violations should be aimed at the sites hosting the material. This site does not host any of the streaming media and the owner has not uploaded any of the material to the video hosting servers. Anyone can find the same content on Google Video or YouTube by themselves.
The owner of this site cannot know which documentaries are in public domain, which has been uploaded to e.g. YouTube by the owner and which has been uploaded without permission. The copyright owner must contact the source if he wants his material off the Internet completely.